Search Result

Results for "

Ferroptosis-IN-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ferroptosis (11) Antibiotic (2) Apoptosis (5) Autophagy (5) Bacterial (2) FLT3 (3) Glutathione Peroxidase (1) Isotope-Labeled Compounds (1) NF-κB (2) Oxidative Phosphorylation (1) Raf (3) STAT (2) VEGFR (3)
By Research Areas:	Cancer (11) Infection (2) Inflammation/Immunology (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Ferroptosis AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14655

Sulfasalazine 25+ Cited Publications NSC 667219	NF-κB Autophagy Apoptosis Ferroptosis Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 *ferroptosis* inducer .

HY-N11885

*Ferroptosis-IN-1*	Ferroptosis	Cancer
Ferroptosis-IN-1 is a A. campylantha diterpenes. Ferroptosis-IN-1 inhibits *ferroptosis* with an EC₅₀ value of 10 μM. Ferroptosis-IN-1 can be used for neuroinflammation diseases research ^[1].

HY-145595

Ferroptosis inducer-1

Ferroptosis Cancer

Ferroptosis inducer-1 (compound BX-3a) is a Ferroptosis inducer with antitumor potential ^[1].

Ferroptosis inducer-1	Ferroptosis	Cancer
Ferroptosis inducer-1 (compound BX-3a) is a *Ferroptosis* inducer with antitumor potential ^[1].

HY-162065

N6F11	Ferroptosis	Cancer
N6F11 is a *ferroptosis* inducer, and can trigger the degradation of glutathione peroxidase 4 (GPX4) specifically in cancer cells. N6F11 can be used for ferroptosis study .

HY-14655S1

Sulfasalazine-d3,15N NSC 667219-d₃,¹⁵N	Antibiotic Autophagy NF-κB Apoptosis Bacterial Ferroptosis Isotope-Labeled Compounds	Infection Inflammation/Immunology Cancer
Sulfasalazine-d₃, ¹⁵N is ¹⁵N and deuterated labeled Sulfasalazine (HY-14655). Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 *ferroptosis* inducer .

HY-10201A

Sorafenib Tosylate Maximum Cited Publications 172 Publications Verification Bay 43-9006 Tosylate	Raf VEGFR FLT3 Autophagy Ferroptosis Apoptosis	Cancer
Sorafenib Tosylate (Bay 43-9006 Tosylate) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for *Raf-1* and B-Raf, respectively. SorafenibTosylate is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib Tosylate induces autophagy and apoptosis. Sorafenib Tosylate has anti-tumor activity. Sorafenib Tosylate is a *ferroptosis* activator .

HY-10201

Sorafenib Maximum Cited Publications 172 Publications Verification Bay 43-9006	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC₅₀s of 6 nM and 20 nM for *Raf-1* and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC₅₀s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a *ferroptosis* activator .

HY-153190A

W1131 TFA	Ferroptosis STAT	Cancer
W1131 TFA is a potent STAT3 inhibitor that induces ferroptosis. W1131 inhibits cancer progression in subcutaneous xenograft, organoid, and PDX models of gastric cancer. W1131 effectively alleviates cancer cell chemoresistance to 5-FU (HY-90006). W1131 regulates the cell cycle, DNA damage response, and oxidative phosphorylation, including the IL6-JAK-STAT3 pathway and the ferroptosis pathway .

HY-138153

JKE-1674 1 Publications Verification	Glutathione Peroxidase Ferroptosis	Cancer
JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by *ferroptosis* inhibitors .

HY-153190

W1131	Oxidative Phosphorylation STAT Ferroptosis	Cancer
W1131 is a potent STAT3 inhibitor, triggering *ferroptosis. W1131 suppresses cancer progression in gastric cancer cell subcutaneous xenograft model, organoids model, and PDX model. W1131 effectively alleviates chemical resistance of cancer cells to 5-FU (HY-90006). W1131 regulates cell cycle, DNA damage response, and oxidative phosphorylation, including IL6-JAK-STAT3* pathway and *ferroptosis* pathway .

HY-10201S2

Sorafenib-13C,d3 1 Publications Verification	Raf VEGFR FLT3 Autophagy Apoptosis Ferroptosis	Cancer
Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N11885

*Ferroptosis-IN-1*	Structural Classification Ophryosporus axilliflorus Hieron. Terpenoids Labiatae Source classification Diterpenoids Plants	Ferroptosis
Ferroptosis-IN-1 is a A. campylantha diterpenes. Ferroptosis-IN-1 inhibits *ferroptosis* with an EC₅₀ value of 10 μM. Ferroptosis-IN-1 can be used for neuroinflammation diseases research ^[1].

Cat. No.	Product Name	Chemical Structure

HY-10201S2

Sorafenib-13C,d3 1 Publications Verification
Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

Sorafenib-13C,d3

1 Publications Verification

Sorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

HY-14655S1

Sulfasalazine-d3,15N
Sulfasalazine-d₃, ¹⁵N is ¹⁵N and deuterated labeled Sulfasalazine (HY-14655). Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 *ferroptosis* inducer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks